Genomic Valley Biotech Limited has notified BSE of an upcoming board meeting, scheduled for Friday, May 29, 2026, at its registered office located at 4 KM Stone, Berri Chhara Road, Tanda Heri, Tehsil Bahadurgarh, District Jhajjar, Haryana. The intimation, dated May 18, 2026, was filed by Managing Director Yogesh Agrawal under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Board Meeting

The board meeting has been convened to transact the following key business items, subject to the permission of the Chair:

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's internal code for prevention of insider trading, the trading window for dealing in the securities of Genomic Valley Biotech has been closed. The closure applies to Directors, Key Managerial Personnel (KMPs), Promoters, Promoter Group members, and other Designated Persons covered under the code.

The key details of the trading window closure are as follows:

The filing was digitally signed by Yogesh Agrawal, Managing Director (DIN: 01165288), on May 18, 2026.

Genomic Valley Biotech Limited has submitted its quarterly compliance certificate to BSE Limited pursuant to Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended March 31st, 2026. The certificate, dated April 14th, 2026, demonstrates the company's adherence to regulatory requirements governing depositories and participants.

Regulatory Compliance Filing

The certificate was filed by Managing Director Yogesh Agrawal with DIN 01165288, who digitally signed the document on April 14th, 2026. The submission was made to BSE Limited's Listing Department and Corporate Relationship Department at their Mumbai office.

Registrar Confirmation

Beetal Financial & Computer Services (P) Ltd, serving as the SEBI-approved Category I Registrar & Share Transfer Agent (Registration No. INR 000000262), provided comprehensive confirmation regarding dematerialization processes. The registrar confirmed that securities received from Depository Participants during the quarter ended March 2026 were properly processed and confirmed to the depositories.

Dematerialization Process Compliance

The registrar's certificate confirms several critical compliance aspects:

• Securities received for dematerialization were confirmed (accepted/rejected) to depositories
• All securities in the certificates have been listed on stock exchanges where previously issued securities are listed
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Depositories' names were substituted in the register of members as registered owners within the prescribed 15-day period

Company Information

Genomic Valley Biotech Limited operates from its registered office located at 4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil Bahadurgarh, District Jhajjar, Haryana. The company holds CIN L01122HR1994PLC033029 and maintains its corporate communications through established channels including email and website platforms.

This quarterly filing represents standard regulatory compliance for listed companies, ensuring transparency in share transfer and dematerialization processes as mandated by SEBI regulations.